A Phase I Study of Positron Emission Tomography With 89Zr-Df-IAB22M2C in Patients With Selected, Metastatic Solid Malignancies (Non Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma Head and Neck, Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma

Trial Profile

A Phase I Study of Positron Emission Tomography With 89Zr-Df-IAB22M2C in Patients With Selected, Metastatic Solid Malignancies (Non Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma Head and Neck, Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs IAB 22M2C (Primary)
  • Indications Cancer; Graft-versus-host disease
  • Focus Adverse reactions; Diagnostic use
  • Sponsors ImaginAb Inc
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
    • 02 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 May 2018.
    • 04 Apr 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top